Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Harmony Biosciences Holdings

Harmony Biosciences
Regional

Harmony Biosciences Launches Early Trial of Promising Orexin Agonist

December 1, 2025November 30, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has begun dosing participants in a Phase 1 clinical study of BP1.15205, a next-generation orexin 2 receptor agonist positioned as …

Harmony Biosciences Launches Early Trial of Promising Orexin Agonist Read More

Harmony Biosciences
Regional

Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences

November 30, 2025November 28, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will showcase its strategy and pipeline to the investment community next week, with executives slated to appear at three major …

Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences Read More
Harmony Biosciences
Regional

Harmony Biosciences Surges on Strong WAKIX Growth as Cash Position Climbs to $778M

November 16, 2025November 13, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences posted another quarter of rapid expansion, driven by accelerating demand for its flagship narcolepsy therapy WAKIX® and a late-stage pipeline approaching multiple Phase 3 …

Harmony Biosciences Surges on Strong WAKIX Growth as Cash Position Climbs to $778M Read More

Harmony Biosciences
Regional

Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights

October 4, 2025October 2, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported topline results from its Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome (FXS), announcing that the trial …

Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights Read More
Harmony Biosciences
Regional

Harmony Biosciences to Present at Cantor Global Healthcare Conference

August 25, 2025August 24, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New …

Harmony Biosciences to Present at Cantor Global Healthcare Conference Read More

Harmony Biosciences
Regional

Harmony Biosciences Delivers Strong Q2 Growth, Advances Late-Stage Pipeline

August 11, 2025August 8, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) reported another quarter of double-digit revenue growth and solidified its position as a profitable, late-stage biotech leader, driven by continued momentum …

Harmony Biosciences Delivers Strong Q2 Growth, Advances Late-Stage Pipeline Read More
Harmony Biosciences
Regional

Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment

June 16, 2025June 15, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences recently revealed compelling preclinical data for BP1.15205, a highly potent and selective orexin 2 receptor (OX2R) agonist, at the 39th Annual Meeting of the …

Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment Read More

Harmony Biosciences
Regional

Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation

June 9, 2025June 8, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently announced the resolution of its patent litigation against Lupin Limited regarding a generic version of WAKIX® (pitolisant hydrochloride). The …

Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation Read More
Harmony Biosciences
Regional

Harmony Biosciences to Join Fireside Chat at Goldman Sachs Global Healthcare Conference

June 8, 2025June 7, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) announced its management team will join a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL, on …

Harmony Biosciences to Join Fireside Chat at Goldman Sachs Global Healthcare Conference Read More
Harmony Biosciences
Regional

Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome

April 14, 2025April 14, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study evaluating ZYN002, a potential treatment for Fragile X syndrome (FXS). The …

Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome Read More

Posts pagination

Previous 1 2 3 4 Next

Trending News

  • Teleflex Sets 34-Cent Quarterly Dividend for December

  • Pennsylvania Pitches $285M Plan for U.S. Space Academy

  • Chester County Education Awards Draw 425 Nominations

  • Kennett Square Weighs Housing Expansion, Parking Changes

  • West Whiteland to Appeal Exton Square Mall Redevelopment Ruling

Subscribe for Updates

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Matylda Szydelko

Woman Faces 10 Charges After Check Stolen From Mailbox

November 17, 2026November 17, 2026

robbery suspect

Gunpoint Robbery in Kennett Square Sparks Search for Suspect

November 17, 2026November 16, 2026

Police News

Overnight Theft Spree Hits Four North Coventry Neighborhood Streets

November 16, 2026November 16, 2026

Copyright © 2026 MyChesCo.